Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

Leukemia

Volumn 21, Issue 11, 2007, Pages 2240-2245

  DiJoseph, J F ^a   Dougher, M M ^a   Armellino, D C ^a   Evans, D Y ^a   Damle, N K ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTILEUKEMIC AGENT; CALICHEAMICIN DERIVATIVE; CD22 ANTIGEN; CMC 544; CMC 676; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BONE MARROW CELL; CANCER INHIBITION; CANCER REGRESSION; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOMA CELL; MALE; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; XENOGRAFT;

EID: 35548931579     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404866     Document Type: Article

References (29)

1. Pui C-H, Evans E. Treatment of acute lymphoblastic leukemia. New Engl J Med 2006; 354: 166-178.
2. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society Inc.: Atlanta, GA, 2006, pp 1-56.
3. Stewart BW, Kleihus P (eds) World Cancer Report IARC Press: Lyon, 2003, Pages 1-352.
4. Parkins DM, Whelan SL, Farley J, Teppo L, Thomas DB. Cancer incidence in 5 continents. IARC: Lyon, Vol. VIII. IARC Scient. Publ. No. 155 2002, pp 1-1286.
5. Marugame T, Kamo K-I, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan 2000. Jpn J Clin Oncol 2006; 36: 668-675.
6. Hamann P, Hinman L, Hollander I, Beyer C, Lindh D, Holcomb R et al Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj Chem 2002; 13: 47-58.
7. Berger M, Leopold L, Dowell J, Korth-Bradley J, Sherman M. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs 2002; 20: 395-406.
8. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG et al. The addition of gentuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity. Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108: 13a.
9. Advani A, Gisselbrecht EGC, Rohatiner A, Rosen S, Smith MR, Boni J et al. Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). Blood 2005; 106: 230a.
10. Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood 2006; 108: 766a.
11. DiJoseph JF, Armellino DC, Boghaert E, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004; 103: 1807-1814.
12. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR et al. Potent and specific anti-tumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004; 10: 8620-8629.
13. Bene M. Immunophenotyping of acute leukemias. Immunol Lett 2005; 98: 9-21.
14. Rezaei A, Adib M, Mokarian F, Tebianian M, Nassiri R. Leukemia markers expression of peripheral blood vs. bone marrow blasts using flow cytometry. Med Sci Monit 2003; 9: 359-362.
15. Gudowius S, Recker K, Laws H-J, Dirksen U, Troger A, Wieczorek U et al. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Pediatr 2006; 218: 327-333.
16. Gökbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects. Ann Hematol 2004; 4: 201-205.
17. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000; 14: 853-858.
18. Borowitz MJ, Carroll WL, Adamson PC, Cairo MS, Goldenberg DM, Wegener WA et al. Effective targeting of leukemic cells in children with B-precursor acute lymphoblastic leukemia treated with anti-CD22 (epratuzumab). A children's Oncology Group Study. Blood 2006; 108: 13 a.
19. Rubin CM, Carrino JJ, Dickler MN, Leibowitz D, and Smith SD, Westbrook CA. Heterogeneity of genetic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci 1988; 85: 2795-2799.
20. Fukushima S, Yamada T, Hashiguchi A, Nakata Y, Hata J. Augmentation of human leukemic cell invasion by activation of a small GTP-binding protein Rho. Exp Hematol 2000; 28: 391-400.
21. Zein N, Sinha A, McGahren W, Ellestad G. Calicheamicin γl: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198-1201.
22. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin pediatric CD33-positive acute lymphoblastic leukemia: First clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17 468-470.
23. Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, DiJoseph JF et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 2006; 28: 675-684.
24. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Ann Rev Immunol 1997; 15: 481-504.
25. Crocket PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22: 337-342.
26. Boue DR, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood 1988; 71: 1480-1486.
27. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T et al. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia 2001; 15: 1185-1192.
28. + acute lymphoblastic leukemia in vitro and in vivo. Br Haematol 2005; 128: 310-317.
29. Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A et al Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 2003; 17: 2247-2248.